Both etanercept (Enbrel) and infliximab (Remicade) have been shown to be effective in the treatment of psoriasis and psoriatic arthritis in randomized, double-blind, placebo-controlled trials.

Infliximab (Remicade®), currently an approved treatment for rheumatoid arthritis and Chron’s disease, is now FDA approved for reducing signs and symptoms of active arthritis in patients with psoriatic arthritis. Data from the Induction and Maintenance of Psoriatic Arthritis Clinical Trial 2 (IMPACT 2) served as the primary basis for the approval. (See summary of 14-week [...]